These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11150804)

  • 1. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 2. Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
    Macdougall IC
    Blood Purif; 2001; 19(2):157-67. PubMed ID: 11150803
    [No Abstract]   [Full Text] [Related]  

  • 3. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
    Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
    Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothesis versus association: the optimal hemoglobin target debate.
    Strippoli GF; Craig JC
    Am J Kidney Dis; 2005 Nov; 46(5):970-3. PubMed ID: 16253741
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anemia and renal failure: efficacy of its control].
    Fort J
    Nefrologia; 2006; 26 Suppl 3():28-32. PubMed ID: 17469424
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.
    Volkova N; Arab L
    Am J Kidney Dis; 2006 Jan; 47(1):24-36. PubMed ID: 16377382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of erythropoietin in predialysis patients.
    Anderson S
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):103-6. PubMed ID: 2024665
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

  • 14. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
    Locatelli F; Aljama P; Bárány P; Canaud B; Carrera F; Eckardt KU; Hörl WH; Macdougal IC; Macleod A; Wiecek A; Cameron S;
    Nephrol Dial Transplant; 2004 May; 19 Suppl 2():ii1-47. PubMed ID: 15206425
    [No Abstract]   [Full Text] [Related]  

  • 15. [Stability of hemoglobin levels: an indispensible paradigm change in medical management].
    Zaoui P; Deray G; Ortiz JP; Rostaing L
    Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H5-7. PubMed ID: 21371678
    [No Abstract]   [Full Text] [Related]  

  • 16. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 17. [Variability of the hemoglobin level: each patient is unique].
    Zaoui P; Deray G; Ortiz JP; Rostaing L
    Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H1-4. PubMed ID: 21371677
    [No Abstract]   [Full Text] [Related]  

  • 18. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease.
    Cianciaruso B; Ravani P; Barrett BJ; Levin A;
    J Nephrol; 2008; 21(6):861-70. PubMed ID: 19034870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.